RxDoctor Payments Data

Saman Jayasinghe, MD

Public Health & General Preventive Medicine · New Orleans, LANPI 1306162672

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Abbott at 54.3% of the total. 2025 is the largest year on record at $695, more than ten times the $25 reported in 2019.

$1,660in general payments, 2019–2025

Across 56 payments — averaging $29.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$902
  • Lilly USA, LLC$241
  • Exact Sciences$103
  • GSK$79
  • Novo Nordisk$62
  • Bayer$49
  • plus $224 from 9 others

What the payments were for

  • Food & beverage$1,62098%
  • Other$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few public health & general preventive medicine providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$5,212
Medicare patients
35
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol26$18,609
OzempicSemaglutide19$18,270
MounjaroTirzepatide14$15,458
JardianceEmpagliflozin14$12,098
Tresiba Flextouch U-100Insulin Degludec11$5,946
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,814
Insulin Lispro Kwikpen U-100Insulin Lispro23$2,639
Gabapentin44$1,748
Omeprazole58$1,389
Albuterol Sulfate HfaAlbuterol Sulfate27$678
Esomeprazole Magnesium11$531
Methocarbamol11$524
Atorvastatin Calcium67$418
Zolpidem Tartrate22$415
Fluticasone Propionate19$395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$16$18,60926 claims
Novo NordiskOzempic$62$18,27019 claims
Lilly USA, LLCMounjaro$241$15,45814 claims
Boehringer IngelheimJardiance$16$12,09814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few public health & general preventive medicine providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other public health & general preventive medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →